Maybe soon you’ll be able to get free shipping, free streaming movies and a cure for the common cold from Amazon.
Yes, you read that right. Amazon is reportedly working on a cure for the common cold.
The company is secretly working on a cure for the condition that causes a runny or stuffy nose, sore throat, cough, sneezing, low-grade fevers and other symptoms, according to CNBC.
Amazon representatives did not immediately respond to a request seeking comment Friday.
CNBC reported that Amazon has assigned more than 100 people in its Grand Challenge division to pursue the cure.
The mission is to develop a vaccine or some other form of treatment, according to the report.
These cleaners kill coronavirus:Lysol, Clorox, Purell products make EPA’s disinfectants list
Can’t find hand sanitzer?:Here’s how to make it at home with vodka or rubbing alcohol
But it might be too early to get your hopes up. The cold, which is usually caused by the rhinovirus, comes in many different forms. And that has made it notoriously hard to cure.
And even if the company comes up with a cure, who will pay for it?
The drug would need to have “almost zero side effects” and there would still be “a major question of whether insurance would pay for it,” venture capitalist and veteran diagnostics executive Mike Pellini told CNBC.
The market opportunity for Amazon is obvious. American adults get about two to three colds per year, and they typically last about seven to 10 days, according to the Centers for Disease Control and Prevention.
The best way to protect yourself from getting a cold is to wash your hands often with soap and water, avoid touching your eyes, nose and mouth, and avoid people who are sick, according to the CDC.
Follow USA TODAY reporter Nathan Bomey on Twitter @NathanBomey.
Prohibida la reproducción parcial o total. Todos los derechos reservados de Rubicon, Global Trade, Customs & Business Partnership, S.C., del Autor y/o Propietario original de la publicación. El contenido del presente artículo y/o cualquier otro artículo, texto, boletín, noticia y/o contenido digital, entre otros, ya sea propio o de tercero alguno, publicado en nuestra página de internet u otros medios digitales, no constituye una consulta particular y por lo tanto Rubicon, Global Trade, Customs & Business Partnership, S.C., sus colaboradores, socios, directivos y su autor, no asumen responsabilidad alguna de la interpretación o aplicación que el lector o destinatario le pueda dar.